Our colleagues have previously demonstrated that other miRNAs (miR-96, miR-217 and miR-27a) function in pancreatic cancer by directly or indirectly affecting KRAS activity, a process that involves PI3K/AKT or RAF-MEK-ERK signaling cascades [25, 48, 49]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.